A new study demonstrates that Nevisense can predict atopic dermatitis in Newborns

SciBase Sweden

Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ)
Tel: [phone]
E-mail: [e-mail]

About SciBase and Nevisense

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ).  Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/a-new-study-demonstrates-that-nevisense-can-predict-atopic-dermatitis-in-newborns,c4308967

The following files are available for download:

https://mb.cision.com/Main/12371/4308967/3938901.pdf

PR draft Mt Sinai prediction of AD

 

View original content:https://www.prnewswire.co.uk/news-releases/a-new-study-demonstrates-that-nevisense-can-predict-atopic-dermatitis-in-newborns-302689570.html